Our attorneys will review Trasylol cases in Fargo and throughout North Dakota and Minnesota.
Trasylol is a drug that was FDA approved for use in the United States in 1993 to control bleeding in patients undergoing open heart surgery and to reduce the need for blood transfusions. The drug works by blocking enzymes that dissolve blood clots.
A study published by the New England Journal of Medicine in January 2006 shows that Trasylol (generic name aprotinin) increases the risk of kidney failure following heart surgery by more than 2 ½ times (259%).
Many people who were given Trasylol do not know they received it, and medical records need to be reviewed to find out if it was administered.
The study also shows that cheaper alternatives to Trasylol are as effective in limiting blood loss but do not increase the risk of kidney damage.
The manufacturer of the drug, Bayer AG based in Leverkusen, Germany, and its U.S. subsidiary with offices in suburban Pittsburgh, Pennsylvania, insist that the study in the New England Journal is flawed, and that the drug is safe.
The FDA calls the study a “complicated analysis based on a large observational database” and says the agency is working to gather information to evaluate Trasylol’s safety.
If you or someone you know underwent open heart surgery and had kidney problems (with or without dialysis) soon afterward, usually during the same hospitalization when the heart surgery was done, please contact us.
Contact us if you have any questions concerning this case please feel free to contact Darcie Wahl at 701-237-3166 or toll-free 877-237-3166 or by e-mail at: email@example.com